Sixty-one consecutive adult patients with leukaemia, primary myelofibrosis or myelodysplastic syndrome with an HLA-identical or one antigen mismatched family donor were randomised to allogeneic transplantation with PBPC or BM. Progenitor cells were mobilised into the blood by giving the donors 10 g/kg/day G-CSF subcutaneously for 5-7 days. G-CSF was not given to patients after transplantation. The time to neutrophil counts Ͼ0.5 ؋ 10 9 /l was 17 days (95% CI 15.2-18.8 days) in the PBPC group compared to 23 (95% CI 20.3-25.7 days) in the BM group (P = 0.0005). The time to platelet counts Ͼ20 ؋ 10 9 /l was 13 days (95% CI 11.7-14.3 days) in the PBPC group and 21 days (95% CI 18.7-23.3 days) in the BM group (P = 0.0005). Acute GVHD of grades II-IV developed in six patients transplanted with PBPC and three patients transplanted with BM. The numbers of patients with chronic GVHD were 15 and 8, respectively. Transplant-related mortality and leukaemia-free survival showed no significant differences. Transplantation with PBPC appears preferable for the recipient due to faster neutrophil and platelet recovery. However, the final conclusion can not be drawn before long-term results on chronic GVHD and relapse incidence in longer randomised trials are available. Bone Marrow Transplantation (2000) 25, 1129-1136. Keywords: blood progenitor cells; allogeneic bone marrow transplantation; G-CSF High-dose chemotherapy followed by autologous PBPC rescue results in earlier engraftment compared to similar therapy followed by autologous BM transplantation.
High-dose chemotherapy followed by autologous PBPC rescue results in earlier engraftment compared to similar therapy followed by autologous BM transplantation. [1] [2] [3] [4] [5] The first report using PBPC as a source of haematopoietic stem cells for allogeneic transplantation appeared in 1989. 6 In the following years there was increasing use of PBPC, but documentation of the advantages of this new procedure based on randomised studies has been lacking. [7] [8] [9] [10] [11] [12] [13] [14] [15] Nevertheless, a massive switch from marrow to blood progenitor cells has taken place since 1995. In 1996, a quarter of all allogeneic transplants with family donors carried out in Europe were performed with PBPC, and since then the number has further increased. 16 In June 1994 we started a randomised trial comparing allogeneic transplantation with PBPC and BM at The National Hospital, Oslo. 17 In 1995, the European Group for Blood and Marrow Transplantation (EBMT) initiated a similar trial except the patients were given growth factor daily after transplantation and three doses instead of four of methotrexate as part of their GVHD prophylaxis. 18 Preliminary results from the latter trial have indicated no significant differences concerning the incidence of moderate to severe acute GVHD, transplantrelated mortality and leukaemia-free survival. There was evidence that transplantation of PBPC resulted in faster platelet and possibly also neutrophil recovery. A randomised study in Brazil showed a faster platelet recovery in the PBPC group compared to the BM group and similar neutrophil recovery for both groups, 19 and a French randomised trial showed similar results. 20 The impact of PBPC transplantation on chronic GVHD is still uncertain, but data from Seattle and other groups suggest a higher incidence of chronic GVHD after PBPC than after BM grafting. [21] [22] [23] [24] [25] Our study is the first single centre prospective trial comparing PBPC and BM allogeneic transplantation.
Patients and methods

Patients
All consecutive patients in Norway accepted for transplantation, aged 15-60 years with a family donor were evaluated for inclusion in the study if they had a diagnosis of AML, ALL, CML, primary myelofibrosis (PMF) or myelodysplastic syndrome (MDS).
From June 1994 until February 1999, 133 patients received an allogeneic stem cell transplant in our unit. Forty-seven patients with no family donor were transplanted with cells from an unrelated donor. Of the remaining 86 patients, 25 patients were not randomised for various reasons (Figure 1) . Thus, 31 patients were finally randomised to PBPC and 30 patients to BM. The age, sex, and diagnoses of all 61 randomised recipients are given in Table 1 .
If ABO incompatibility was found between recipient and donor (titer of antibodies present (IgG or IgM) Ͼ1/32 in the recipient), plasmapheresis was performed until titer Ͻ1/32. 
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Study design and statistical analysis
The 61 patients were stratified according to age (Ͼ30 and Ͻ30 years of age), and randomised in blocks of six, three for each type of cell harvest. Analysis was performed according to the principle of 'intention to treat'. Patients who died before engraftment were censored. We applied a non-parametric comparison between the two groups according to the Wilcoxon signed rank sum test. Outcome probabilities were calculated by the method of and curves compared using the log-rank test. We required a significance of 5% unilaterally. In the results, however, the P values represent bilateral 5% significance. The study was approved by the Regional Committee for Medical Research Ethics, Health Region II, and written informed consent was obtained from all recipients and donors. 
Donors
The family donors were between 15 and 61 years of age. Among the 31 donors randomised to PBPC, 26 were HLAidentical and five were one A, B, or DR HLA-antigen mismatched with the recipient. Among the 30 donors randomised to BM, one had one HLA-A, B or DR antigen mismatch to the recipient, the others were HLA-identical. The donors had to be in good health and aged above 15 years to be accepted. Each donor went through a physical examination prior to entering the study. Performance status, complete blood count, clinical chemistry, and bone marrow aspirate examination were documented pre-study. The median age, sex, and CMV status of all donors entered into this study are summarized in Table 1 . Distinctive differences between donors randomised to PBPC collection or BM harvest were not observed.
Among the donors who underwent PBPC harvesting, 19 had one leukapheresis, 10 required two, and one donor required three leukaphereses in order to collect the target cell number of 2 ϫ 10 6 CD34 + cells/kg body weight (bw) of the recipient. Central venous access was not necessary in any of the PBPC donors. The outcome for the donors will be discussed in a separate paper.
Harvest procedures
Donors randomised to donate BM were harvested from the posterior iliac crests under general anaesthesia. A minimum of 2 ϫ 10 8 nucleated cells/kg recipient bw was required for transplantation. Donors randomised to undergo PBPC collection were treated with filgrastim (r-metHuG-CSF) (Neupogen, Hoffmann-La Roche, Basel, Switzerland) at a dose of 10 g/kg/day subcutaneously for 5 consecutive days. 27 PBPC were collected by leukapheresis on the 5th day of treatment approximately 4 to 8 h after the last injection of G-CSF. Automated blood cell separators with either continuous-flow (Cobe Spectra, Denver, CO, USA) or intermittent flow (Haemonetics, Braintree, MA, USA) were used. A minimum of 2 ϫ 10 6 CD34 + cells/kg recipient bw was collected. CD34
+ haematopoietic progenitor cells were enumerated using the Nordic flow cytometry standards for CD34 + cell enumeration. 28 The product was infused into the patient on the same day (defined as day 0 for the recipient). If the first leukapheresis failed to procure 2 ϫ 10 6 CD34 + cells/kg, the treatment with filgrastim was continued and a second leukapheresis was performed the next day (redefined as day 0 for the recipient). The procedure was repeated a third time if necessary.
If ABO incompatibility existed between donor and recipient with a significant titer of antibodies (IgG or IgM) Ͼ1/256 in the donor, the plasma was separated from the graft. Other manipulations of the graft were not performed.
Conditioning
Conditioning therapy was identical for all patients and consisted of busulphan 4 mg/kg/day p.o. on day −7 to −4, and cyclophosphamide 60 mg/kg/day i.v. on day −3 and −2. Patients with AML, FAB classification M4/M5, or ALL received intrathecal methotrexate (MTX) 12 mg/day on day −8 and −4. CNS radiation was not a part of the conditioning in any patient.
Prophylaxis and treatment of GVHD
GVHD prophylaxis consisted of cyclosporin A (CsA) and MTX. CsA was started on day −1 and tapered from day +180 unless active GVHD required continuation of the drug. CsA was given as an 8-h i.v. infusion until oral administration became feasible. Dosing of CsA was monitored by regular measurements of CsA blood concentrations, aiming at trough levels between 300 and 400 ng/ml days 0-30, 250-400 ng/ml days 30-60 and 125-250 ng/ml until day 180. In addition, MTX was injected i.v. on day +1 (15 mg/m 2 ) and days +3, +6 and +11 (10 mg/m 2 ) providing there were no signs of serious liver toxicity (serum bilirubin Ͼ100 mol/l, ascites or edema). Steroids were not given as prophylaxis. If acute GVHD (grade II-IV) developed, i.v. methylprednisolone 2 mg/kg was administered daily and later replaced by oral prednisolone, and tapered according to clinical response. Acute GVHD was graded continuously according to the Glucksberg criteria. 29 The surveillance of GVHD was supplemented with skin biopsies on days +14, +28 and +100. Chronic GVHD was classified as described by Shulman et al. 30 
Supportive care and clinical monitoring
All patients received prophylactic administration of acyclovir from day −2 until day +28. In addition they were given trimethoprim/sulphamethoxazol before the transplantation until day −4, and after transplantation when ANC exceeded 1.0 ϫ 10 the patients were given amphotericin B p.o. from day −4 and during aplasia. They did not receive G-CSF after transplantation. Patients with AML, FAB classification M4/M5, or ALL were given intrathecal methotrexate 12 mg four times post transplantation.
The patients' histories, performance status, vital signs, complete blood counts, and clinical chemistry were recorded pre-study, at regular intervals during hospitalisation and at each follow-up visit (ie at least at 3, 6 and 12 months after transplantation). BM aspirates were performed pre-study and on day +28, and at 3, 6, 9 and 12 months after grafting in order to evaluate the remission status. The chimeric state of the patient was evaluated.
Study endpoints
The primary objective was to establish whether allogeneic PBPC transplantation reduced the number of days until the absolute neutrophil count (ANC) reached 0.5 ϫ 10 9 /l, and the platelet count reached 20 ϫ 10 9 /l as compared to allogeneic BM transplantation. The duration of the first hospital stay, defined as the number of days from the day of transplantation until the patient was discharged, was estimated. To be discharged the patients had to be in a good general condition and able to drink and eat sufficiently. All intravenous therapy had to be abolished.
The incidence and severity of GVHD, the number of transfusion units of erythrocytes and platelets, the number of days of treatment with antibiotics, the overall survival and the leukaemia-free survival were also recorded.
Results
Engraftment and haematopoietic recovery
One patient died 8 days and another 21 days after receiving PBPC without haematopoietic recovery. Causes of death were multiorgan failure and infections, respectively. One patient randomised to PBPC was excluded due to the need for additional BM as the stem cell source.
The remaining patients, 28 patients in the PBPC group and 30 in the BM group, were evaluable for neutrophil and platelet recovery. Patients grafted with allogeneic PBPC reached a granulocyte level of 0.5 ϫ 10 9 /l at a median time of 17 days (95% confidence interval (CI) 15.2-18.8 days). In the BM group the recovery time was 23 days (95% CI 20.3-25.7 days, P = 0.0005) (Figure 2 ). The median time to reach an unsupported platelet count of 20 ϫ 10 9 /l was 13 days (95% 11.7-14.3 days) in the PBPC group and 21 days (95% CI 18.7-23.3 days) in the BM group (P = 0.0005) (Figure 3 ). In the PBPC group, one patient needed respiratory support and was treated with anti-CMV agents and other BM suppressive agents. This patient failed to achieve an unsupported platelet count above 20 ϫ 10 9 /l before day +90.
The recipients of PBPC needed a median of six units of erythrocyte transfusions and six units of platelets. In the BM group, the corresponding figures were six and 11 units. The difference in the need for platelet transfusions was significant (P = 0.006) ( Table 2 ). The median number of (range 1.8-7.7) and 2.7 ϫ 10 6 (range 0.7-4.7) per kg recipient bw in the BM graft (n = 20).
Graft-versus-host disease
Twenty-eight patients in the PBPC arm and 30 patients in the BM arm were evaluable. Twenty-five out of 28 in the PBPC group received all four doses of i.v. MTX on days 1, 3, 6 and 11. The remaining three patients had only three MTX injections due to liver toxicity. In the BM group, 27 out of 30 patients received four doses of MTX. The remaining three had three doses only, also due to liver toxicity. Maximum grades of acute GVHD are given in Table 3 . The The figure represent median with range in brackets. probability of developing acute GVHD grade II-IV is shown in Figure 4 . Among the PBPC transplanted patients 12 patients developed acute GVHD. Six of them had grade II-IV GVHD of which two had steroid refractory acute GVHD. In the BM group, the corresponding numbers were eight (P = 0.159), three (P = 0.178) and none. Until August 1999, 27 patients in the PBPC arm and 30 patients in the BM arm were evaluable for chronic GVHD, having survived 3 months and with a median observation time of 27 months (range 0-59) and 27 months (range 2-58) respectively. In the PBPC arm 15 patients had chronic GVHD (five with one HLA-antigen mismatch), of whom four had extensive GVHD, while in the BM group the corresponding numbers were eight and two (no HLA-antigen mismatches).
Other complications
Two patients in the PBPC group died of multiorgan failure and infections on day +8 and day +21, respectively, and were thus not defined as engraftment failure. They were both over 50 years of age. Other complications such as septicaemia documented by positive blood cultures, cytomegalovirus reactivation and veno-occlusive disease are given in Table 4 . There were no significant differences between the treatment groups. All patients in the PBPC arm had fevers and needed a median of 10 days of treatment with antibiotics, while in the BM arm two patients did not develop fever, and the median number of days with antibiotic treatment was 13.5 (P = 0.018) ( Table 2 ). The duration of the first hospital stay was a median of 31 days (range 19-96) after PBPC and 34 days (range 20-83) after BM ( Table 2) . The difference between the two groups was not significant (P = 0.47) ( Figure 5 ). The median number of hospital days within the first 100 days was 34.5 (range 19-100) and 36 (range 24-100), respectively. The difference was not significant (P = 0.148).
Causes of death, relapse incidence, and leukaemia-free survival
As of 8 August 1999, 24 patients in the PBPC arm and 22 patients in the BM arm were alive at median of 34 months (range 7-62) and 36 months (range 8-61) respectively. Of 30 patients grafted with PBPC, four patients died before day +100 (days +8, +21, +77 and +98) and two additional patients died during the first year of follow-up (days +165 and +167). In the BM group none died before day +100, seven patients died during the first year post-transplant (days +137, +212, +240, +252, +287, +295 and +302), and Table 4 Other early complications one patient after 367 days. The causes of death are summarized in Table 5 .
In the PBPC group, one patient relapsed on day +131 and died. In the BM arm, nine patients relapsed. Seven patients relapsed within the first year after transplantation of whom four patients are dead. Two patients relapsed after more than 1 year after transplantation and are still alive. The characteristics of the relapsed patients are given in Table 6 .
The disease-free survival (P = 0.11) and the overall survival (P = 0.84) are shown in Figures 6 and 7 .
Discussion
We initiated the first randomised investigation designed to compare the initial clinical course after transplantation of PBPC or BM from family donors. The advantage of our study is that it comes from one centre, and that patients have been treated consistently according to a single protocol. In contrast to most other protocols, we did not give patients G-CSF post transplant. This makes the results concerning the haematopoietic recovery particularly interesting. A disadvantage is the long time it takes one small centre to accrue a sufficient number of patients. The heterogeneity between the treatment groups, especially regarding HLA-mismatch and poor risk patients might have influenced the final outcome. This makes the comparison less reliable regarding GVHD and relapse rate.
Our study shows that transplantation of PBPC results in a faster neutrophil and platelet recovery compared to BM. The results are more striking than those shown in earlier publications [18] [19] [20] and in accordance with the results of randomised trials comparing PBPC and BM autografting. 4, 5 The differences observed in this allogeneic setting are even more marked concerning neutrophil recovery. 5 In the EBMT protocol, G-CSF was given post transplant to all patients. 18 It is possible that G-CSF treatment will reduce the difference in regeneration time between these transplantation techniques. Another issue is whether the period of CR = complete remission; rel = relapse; CF = chronic phase; LFS = leukaemia-free survival; + = alive. aplasia may be shortened, by giving G-CSF after transplantation. So far the trials performed to elucidate this question indicate only a benefit concerning the neutrophil recovery without any significant impact on the platelet recovery. 31, 32 The possible long-term effects on haematopoietic reconstitution, GVHD, and leukaemia-free survival remain uncertain. Our study does not clarify whether the number of CD34 + cells infused affects the neutrophil and platelet recovery.
Other studies have revealed that the higher number of progenitor cells infused, the shorter the period of aplasia. [33] [34] [35] Some authors recommend a number of CD34 + cells between 3 and 4 ϫ 10 6 /kg recipient bw. Others suggest a number above 4 × 10 6 /kg as an optimal yield. In our setting the median number was 3.1. To obtain a higher number of cells, further phereses would have been required. This would have increased the discomfort for the donor, and possibly made platelet transfusions necessary. Consequently this would make the PBPC harvest less beneficial in comparison to BM harvest. Nevertheless infusion of CD34 + cell numbers higher than 2.0 ϫ 10 6 /kg recipient bw seems to be enough to shorten the period of aplasia. All our patients transplanted with PBPC have maintained stable haematopoietic reconstitution. Still, the goal must be to develop techniques that will provide sufficient progenitor cells in a single leukapheresis in all patients.
Our results support the conclusions in other studies that patients transplanted with PBPC require slightly less antibiotic treatment for infections, and fewer transfusions of platelets. 13, 15, 20 Despite the more rapid neutrophil recovery, the duration of the first hospital stay post transplant was not significantly shorter in the PBPC group in our trial. This might in part be due to an earlier outbreak of acute GVHD requiring i.v. steroids. Other studies have revealed a slightly shorter hospital stay, 13, 36 but readmission seems to be more frequent among the PBPC recipients. A short hospital stay is important for the patients and their families, and could also have economic implications, an issue, which is not estimated in our study. A Canadian trial 37 suggests that PBPC transplantation is cost equivalent to allogeneic BM transplantation.
We recorded a slightly higher incidence of acute GVHD in the PBPC grafted patients although the difference was not significant (Table 3 ). The most likely contributing factor is the higher number of patients with one HLA-antigen mismatch in the PBPC group (5 vs 1). The significantly higher number of T lymphocytes in the PBPC grafts probably also played a role. 38 A similar trend was recorded with relevance to chronic GVHD. Again the unequal distribution of HLA mismatches may explain the difference. Other investigators have suggested a higher risk of chronic GVHD associated with PBPC transplantation. [21] [22] [23] [24] [25] The apparently lower rate of relapse in the PBPC group is difficult to evaluate. It could reflect small numbers only, or it could be due to the higher number of patients with AML transplanted in early relapse in the BM arm than in the PBPC arm. Some authors suggest a lower relapse rate among patients undergoing allogeneic PBPC transplantation, which would be consistent with an enhanced graft-versus-leukaemia (GVL) effect. This has mainly been observed in patients with CML. 39 A larger trial will be required to determine whether allogeneic PBPC exert a more potent GVL effect in humans, as has recently been demonstrated in a mouse model. 40 If ongoing randomised trials confirm a reduced relapse rate among the PBPC recipients, the gain must be balanced against other risks, eg increased chronic GVHD.
The documented advantages of using PBPC as a stem cell source are not impressive from the patients perspective. However, the effects on the donor must also be taken into consideration. As observed by others, 18 ,41 the side-effects and the discomfort for the donor providing PBPC seem to be considerably less than for the BM donor. In our series, preliminary investigation suggests no severe or life-threatening complications linked to any of the harvest procedures. However, the long-term effects of G-CSF treatment on healthy donors are still not known. One major Bone Marrow Transplantation complication following PBPC mobilization has been described, 41 and a few vascular events have occurred, 42 probably making ordinary BM harvest a better alternative for some categories of donors.
In conclusion, the use of PBPC shortens the period of aplasia compared to BM. This advantage alone probably does not justify a change of practice as long as the final outcome for the patient does not change, and the long-term effects of G-CSF in donors are not fully known. However, donor discomfort associated with PBPC harvest is much less pronounced and this tips the balance in favour of PBPC grafts. Cost-effectiveness analysis may also have an impact on the choice of graft. So far we see no rationale for posttransplant treatment with G-CSF.
